Comparative Pharmacology
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus PRILOCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus PRILOCAINE HYDROCHLORIDE.
LIDOSITE TOPICAL SYSTEM KIT vs PRILOCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Prilocaine hydrochloride is an amino amide local anesthetic that reversibly blocks sodium channels in nerve cell membranes, inhibiting nerve impulse propagation.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
Adults: 4 mg/kg (max 200 mg) via infiltration or nerve block; may repeat after 2 hours with 50% of initial dose.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Terminal half-life: 1.5-2 hours (adults, normal hepatic function). Prolonged in neonates (up to 8-12 hours) due to immature hepatic metabolism and reduced clearance; may cause methemoglobinemia. Hepatic impairment increases half-life.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Renal: ~95% as metabolites (primarily o-toluidine and 4-hydroxy-2-methylaniline) and <5% unchanged. Biliary/fecal: minimal (<2%).
Category C
Category C
Local Anesthetic
Local Anesthetic